LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Diagnostics Rapidly Gain Ground in Infectious Diseases Sector

By LabMedica International staff writers
Posted on 22 Dec 2014
Print article
According to a new Frost & Sullivan (Mountain View, CA, USA) analysis, convergence of immunological and molecular tests will help meet growing needs for infectious disease (ID) diagnostics. Although these tests remain expensive, their efficiency and accuracy strengthen their use case.

Frost & Sullivan’s new report “Analysis of the Global Infectious Disease Diagnostics Market” finds the market earned USD 7.91 billion revenue in 2013 and estimates it to reach USD 12.77 billion in 2018. Hepatitis B, hepatitis C, tuberculosis, and sepsis tests are predicted to be the major revenue generators.

The market will continue to develop as unmet technological needs lead to the creation of faster, more capable platforms. Molecular ID-diagnostics is growing fastest, clocking a compound annual growth of 15.3%. “Immunodiagnostics is another segment that continues to expand rapidly owing to cost-effective tests as well as the prevalence of hospital-acquired infections like sepsis and MRSA,” said Frost & Sullivan life sciences industry analyst Aish Vivekanandan, “Molecular methods and immunodiagnostics are expected to complement each other as the need for accurate and rapid diagnostic tests rises.”

Unique disease outbreaks across the globe are further escalating the demand for screening, spurring the ID diagnostic market. While decentralized and rapid tests are a growing trend in the developed world, stringent regulations complicate product development and marketing, and high costs affect the market in developing countries. Another challenge is low product awareness across regions. Companies must invest in clinical studies to prove the efficacy of their products and raise awareness among evidence-driven consumers, especially in the clinical field.

“Many participants are focusing their research on top industry requirements such as product automation, rapidity, specificity, and accuracy,” noted Vivekanandan, “Companies are also striving to expand the scope of diseases their products cover in order to establish their foothold in the global ID diagnostics market.”

The new report is part of Frost & Sullivan’s Life Sciences Growth Partnership Service program. Related studies include: “Global in Vitro Diagnostics Market,” “US Hematology Diagnostics Market,” “Global Next-generation Sequencing Market,” and “Western European Companion Diagnostics Market.” All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

Related Links:
Frost & Sullivan
Analysis of the Global Infectious Disease Diagnostics Market report
Life Sciences Growth Partnership Service program


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more